CorMedix
CRMD
33 hedge funds and large institutions have $10.3M invested in CorMedix in 2018 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 12 increasing their positions, 4 reducing their positions, and 5 closing their positions.
425% more capital invested
Capital invested by funds: $1.96M → $10.3M (+$8.33M)
200% more repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 4
0.15% more ownership
Funds ownership: 2.02% → 2.17% (+0.15%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
3% less funds holding
Funds holding: 34 → 33 (-1)
20% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 5
82% less call options, than puts
Call options by funds: $20K | Put options by funds: $113K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$436K |
| 2 |
EI
EAM Investors
Solana Beach,
California
|
+$356K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$153K |
| 4 |
VF
Virtu Financial
New York
|
+$101K |
| 5 |
Northern Trust
Chicago,
Illinois
|
+$81K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Franklin Resources
San Mateo,
California
|
-$26K |
| 2 |
Group One Trading
Chicago,
Illinois
|
-$21.6K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$8.4K |
| 4 |
Commonwealth Equity Services
Waltham,
Massachusetts
|
-$6K |
| 5 |
Millennium Management
New York
|
-$3K |
CRMD Hedge Fund Activity: Q3 2018 in Review
33 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in CorMedix (CRMD) for Q3 2018, worth a combined $10.3M — up 425% from $1.96M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of CRMD and 4 opened new positions — a net loss of 1 holder — while 4 trimmed existing stakes and 12 added.
The largest buyer was Vanguard Group, adding an estimated $436K. The largest seller was Franklin Resources, cutting an estimated $26K.
- 33 institutional investors held CorMedix (CRMD) as of Q3 2018, down from 34 in Q2 2018.
- Funds reported $10.3M of CorMedix stock for Q3 2018, up 425% quarter-over-quarter.
- 4 funds opened new CorMedix positions in Q3 2018 and 5 closed out, a net change of -1 holder.
- The largest CorMedix buyer in Q3 2018 was Vanguard Group, an estimated $436K added.
- The largest CorMedix seller in Q3 2018 was Franklin Resources, an estimated $26K sold.
Based on aggregated 13F filings for Q3 2018.